According to filings with the U.S. Securities and Exchange Commission, CoapTech is raising $3,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Howard Carolan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About CoapTech
CoapTech is bringing a series of breakthrough medical devices to worldwide markets, leveraging a patented, disruptive platform technology called the Point-of-care Ultrasound Magnet Aligned (PUMA) System. The PUMA Platform will disrupt multiple medical procedures, reducing health care costs, and improving efficiency, safety, quality, patient experience, and access to services around the globe. Invented by Dr. Steven Tropello, a Johns Hopkins-trained critical care physician, the PUMA System enables diagnostic, interventional and therapeutic procedures in hollow organs. The system combines magnetic attraction for device placement guidance, and ubiquitous, low-cost, point-of-care ultrasound for visualization in hollow cavities. Our lead device, the PUMA-G, selected because of its low risk, clear FDA pathway, and strong commercial viability, is for the insertion of Gastrostomy (feeding) tubes. PUMA-G enables a point-of-care (i.e. bedside, as opposed to operating room) procedure for inserting gastrostomy tubes which can be quickly and easily performed by non-surgical providers. By eliminating specialty suites and specialist consultants, PUMA-G will save hospitals money and improve efficiency and safety for this common procedure. PUMA-G has been validated in human anatomy, and has a streamlined regulatory pathway based on FDA presubmission feedback.

To learn more about CoapTech, visit http://www.coaptech.com/

Contact:
Howard Carolan, Chief Executive Officer
443-574-6934
https://www.linkedin.com/in/howard-carolan/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.